Great Basin Scientific Raises US$3.6 Million for Product Launch
|
By LabMedica International staff writers Posted on 24 Jun 2009 |
|
Great Basin Scientific, Inc. (Salt Lake City, UT, USA) raised $3.6 million in bridge funding to support the company through 2009 and the launch of its first product, pending Food and Drug Administration (FDA; Rockville, MD, USA) 510(k) clearance. Returning investors participated in the funding round.
The tests will be sensitive yet simple and easy to perform. An integrated cartridge will hold all reagents and the tests will be executed by a benchtop analyzer, putting the power of highly-complex molecular tests previously found only in large centralized labs, in a simple, 2-3 step test that can be performed in doctor's office or small hospital or clinic lab.
As part of the preparation for an August 2009 clinical trial for its first test--a 50-minute diagnostic test for methicillin resistant Staphylococcus aureus (MRSA) from a positive blood culture--Great Basin Scientific is leading several preclinical studies. The company conducted a successful feasibility study in spring 2009 as it characterized 132 retrospective samples from study collaborators at the Children's Memorial Hospital (Chicago, IL, USA) and Denver Health Hospital (CO, USA). Testing was performed at Great Basin Scientific's lab in Longmont (CO; USA).
"The results of the preclinical study completely met our expectations and kept us right on track as we approach clinical trials," said Rob Jenison, Great Basin Scientific's chief technology officer and vice president of development.
Several major hospitals will serve as beta-testing sites for Great Basin Scientific's point-of-care molecular platform beginning in mid-July, 2009. During beta testing, clinicians will test the analyzers and provide feedback on process flow and functionality. The testing will serve as preparation for the clinical trials scheduled to begin in August 2009.
Future tests will include nosocomial infections. Tests for Streptococcus Group, the most common cause of sepsis and meningitis in newborns, and Human papillomavirus (HPV), the most common sexually transmitted infection of which certain types can lead to cervical cancer are being developed.
Related Links:
Great Basin Scientific, Inc.
Food and Drug Administration
Children's Memorial Hospital
Denver Health Hospital
The tests will be sensitive yet simple and easy to perform. An integrated cartridge will hold all reagents and the tests will be executed by a benchtop analyzer, putting the power of highly-complex molecular tests previously found only in large centralized labs, in a simple, 2-3 step test that can be performed in doctor's office or small hospital or clinic lab.
As part of the preparation for an August 2009 clinical trial for its first test--a 50-minute diagnostic test for methicillin resistant Staphylococcus aureus (MRSA) from a positive blood culture--Great Basin Scientific is leading several preclinical studies. The company conducted a successful feasibility study in spring 2009 as it characterized 132 retrospective samples from study collaborators at the Children's Memorial Hospital (Chicago, IL, USA) and Denver Health Hospital (CO, USA). Testing was performed at Great Basin Scientific's lab in Longmont (CO; USA).
"The results of the preclinical study completely met our expectations and kept us right on track as we approach clinical trials," said Rob Jenison, Great Basin Scientific's chief technology officer and vice president of development.
Several major hospitals will serve as beta-testing sites for Great Basin Scientific's point-of-care molecular platform beginning in mid-July, 2009. During beta testing, clinicians will test the analyzers and provide feedback on process flow and functionality. The testing will serve as preparation for the clinical trials scheduled to begin in August 2009.
Future tests will include nosocomial infections. Tests for Streptococcus Group, the most common cause of sepsis and meningitis in newborns, and Human papillomavirus (HPV), the most common sexually transmitted infection of which certain types can lead to cervical cancer are being developed.
Related Links:
Great Basin Scientific, Inc.
Food and Drug Administration
Children's Memorial Hospital
Denver Health Hospital
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Chagas Disease Test
LIAISON Chagas
New
PSA Test
Humasis PSA Card
Latest Industry News
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
- New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
- Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
- Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration
- Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
- Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
- Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy
- CACLP 2025 Unites Global Innovators in IVD Industry
- Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
- ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- New Partnership Revolutionizes Analyses of Biological Samples
- Medlab Middle East Looks to The Future of Laboratories
- Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience
- bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Simple Blood Test Better Predicts Heart Disease Risk
Cardiovascular diseases (CVDs) are the primary cause of death worldwide. A large proportion of these cases could be prevented by addressing lifestyle and environmental factors such as smoking, poor diet,... Read more
New Blood Test Detects 12 Common Cancers Before Symptoms Appear
Bowel cancer is the fourth most common cancer in the UK, with over 42,000 new diagnoses each year. Detecting bowel cancer in its early stages can be challenging, and as the disease progresses, survival... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
